ArrowArtboardCreated with Sketch.Title ChevronTitle ChevronIcon FacebookIcon LinkedinIcon Mail ContactPath LayerIcon MailPositive ArrowIcon PrintIcon Twitter
Coronavirus

Taiwan's COVID vaccine stocks double after Japanese donations

Tokyo sends 1.24 million AstraZeneca jabs as Taipei snubs China offer

Vaccines airlifted to Taiwan will help the island battle a recent spike in COVID-19 infections.   © Kyodo

TOKYO/TAIPEI (Reuters) -- Japan delivered to Taiwan 1.24 million doses of AstraZeneca 's coronavirus vaccine on Friday for free, in a gesture that will more that double the amount of shots the island has received to date.

Taiwan is battling a spike in domestic infections and has vaccinated only about 3% of its population. Japan has agreed to procure more than 300 million doses of coronavirus vaccines from Pfizer, Moderna and AstraZeneca, more than enough to cover its entire population.

"At the time of the great east Japan earthquake 10 years ago, people in Taiwan sent us a lot of donations promptly. I believe that is etched vividly in the minds of Japanese people," Foreign Minister Toshimitsu Motegi said, announcing the vaccine donation. "Such an important partnership and friendship with Taiwan is reflected in this offer."

The vaccines landed at Taipei's main international airport early afternoon. Taiwan Health Minister Chen Shih-chung said he was "extremely thankful" the shots had arrived at a tense moment in the island's fight against the pandemic, as he reported another 472 new infections.

"I believe it will be very helpful in overall pandemic prevention," he added.

The donation is a triumph for Taiwan President Tsai Ing-wen, who has faced public anger about the slow arrival of vaccines and small protests by the main opposition party, the Kuomintang, outside her offices.

The donation "reflects the results of close exchanges between the Tsai Ing-wen government and the Japanese government over the past five years", Taiwan's ruling Democratic Progressive Party said.

Though Taiwan's share has not been announced, the island will also get shots under a White House plan for the United States to share 25 million surplus COVID-19 vaccine doses with the world.

Taiwan has received only about 860,000 doses so far, mainly AstraZeneca shots, but also a smaller number from Moderna. It has ordered more than 20 million doses from AstraZeneca and Moderna and is also developing its own vaccines.

In an emailed statement to Reuters, Johnson & Johnson said that it had been in "confidential discussions" with Taiwan about providing its COVID-19 vaccine to the island since last year, but gave no details.

The J&J vaccine requires a single dose, rather than the two-shot regimen of most other COVID-19 vaccines.

Like many governments, Taiwan's vaccine plans have been stymied by global shortages.

China, which claims the island as its own territory, has offered vaccines, but Taiwan has repeatedly expressed concern about their safety, and accused China of trying to block Taiwan's vaccine purchases internationally. Beijing denies this.

Japan approved AstraZeneca's vaccine last month and has contracted to buy 120 million doses. But there are no immediate plans to use the shots, amid lingering concerns raised internationally over blood clots.

Sponsored Content

About Sponsored Content This content was commissioned by Nikkei's Global Business Bureau.

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this monthThis is your last free article this month

Stay ahead with our exclusives on Asia;
the most dynamic market in the world.

Stay ahead with our exclusives on Asia

Get trusted insights from experts within Asia itself.

Get trusted insights from experts
within Asia itself.

Try 1 month for $0.99

You have {{numberArticlesLeft}} free article{{numberArticlesLeft-plural}} left this month

This is your last free article this month

Stay ahead with our exclusives on Asia; the most
dynamic market in the world
.

Get trusted insights from experts
within Asia itself.

Try 3 months for $9

Offer ends October 31st

Your trial period has expired

You need a subscription to...

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers and subscribe

Your full access to Nikkei Asia has expired

You need a subscription to:

  • Read all stories with unlimited access
  • Use our mobile and tablet apps
See all offers
NAR on print phone, device, and tablet media

Nikkei Asian Review, now known as Nikkei Asia, will be the voice of the Asian Century.

Celebrate our next chapter
Free access for everyone - Sep. 30

Find out more